Immunogenicity of Monoclonal Antibodies Against Tumor Necrosis Factor Used in Chronic Immune-Mediated Inflammatory Conditions: Systematic Review and Meta-analysis | Allergy and Clinical Immunology | JAMA Internal Medicine | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.204.227.34. Please contact the publisher to request reinstatement.
1.
Baraliakos  X, Listing  J, Fritz  C,  et al.  Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years—early clinical response predicts long-term outcome.  Rheumatology (Oxford). 2011;50(9):1690-1699.PubMedGoogle ScholarCrossref
2.
Perrier  C, Rutgeerts  P.  Cytokine blockade in inflammatory bowel diseases.  Immunotherapy. 2011;3(11):1341-1352.PubMedGoogle ScholarCrossref
3.
Scott  DL.  Biologics-based therapy for the treatment of rheumatoid arthritis.  Clin Pharmacol Ther. 2012;91(1):30-43.PubMedGoogle ScholarCrossref
4.
Baert  F, Noman  M, Vermeire  S,  et al.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease.  N Engl J Med. 2003;348(7):601-608.PubMedGoogle ScholarCrossref
5.
Bartelds  GM, Krieckaert  CL, Nurmohamed  MT,  et al.  Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up.  JAMA. 2011;305(14):1460-1468.PubMedGoogle ScholarCrossref
6.
Bendtzen  K, Geborek  P, Svenson  M, Larsson  L, Kapetanovic  MC, Saxne  T.  Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab.  Arthritis Rheum. 2006;54(12):3782-3789.PubMedGoogle ScholarCrossref
7.
Vermeire  S, Noman  M, Van Assche  G, Baert  F, D’Haens  G, Rutgeerts  P.  Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease.  Gut. 2007;56(9):1226-1231.PubMedGoogle ScholarCrossref
8.
Wolbink  GJ, Vis  M, Lems  W,  et al.  Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis.  Arthritis Rheum. 2006;54(3):711-715.PubMedGoogle ScholarCrossref
9.
Anderson  PJ.  Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles.  Semin Arthritis Rheum. 2005;34(5)(suppl 1):19-22.PubMedGoogle ScholarCrossref
10.
van der Laken  CJ, Voskuyl  AE, Roos  JC,  et al.  Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis.  Ann Rheum Dis. 2007;66(2):253-256.PubMedGoogle ScholarCrossref
11.
Thurlings  RM, Teng  O, Vos  K,  et al.  Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis.  Ann Rheum Dis. 2010;69(2):409-412.PubMedGoogle ScholarCrossref
12.
Stubenrauch  K, Wessels  U, Birnboeck  H, Ramirez  F, Jahreis  A, Schleypen  J.  Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: evaluation of an antidrug antibody ELISA using clinical adverse event–driven immunogenicity testing.  Clin Ther. 2010;32(9):1597-1609.PubMedGoogle ScholarCrossref
13.
Haggerty  HG, Abbott  MA, Reilly  TP,  et al.  Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritis.  J Rheumatol. 2007;34(12):2365-2373.PubMedGoogle Scholar
14.
Weinblatt  ME, Genovese  MC, Schiff  MH,  et al.  Immunogenicity is low and transient with intravenous (IV) abatacept therapy: results from a large pooled analysis of 3985 patients (pts) with rheumatoid arthritis (RA) and up to 8 years' exposure [abstract].  Arthritis Rheum. 2011;63(suppl 10):2191.Google Scholar
15.
de Vries  MK, van der Horst-Bruinsma  IE, Nurmohamed  MT,  et al.  Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis.  Ann Rheum Dis. 2009;68(4):531-535.PubMedGoogle ScholarCrossref
16.
Dore  RK, Mathews  S, Schechtman  J,  et al.  The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis.  Clin Exp Rheumatol. 2007;25(1):40-46.PubMedGoogle Scholar
17.
Yount  S, Sorensen  MV, Cella  D, Sengupta  N, Grober  J, Chartash  EK.  Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis.  Clin Exp Rheumatol. 2007;25(6):838-846.PubMedGoogle Scholar
18.
Liberati  A, Altman  DG, Tetzlaff  J,  et al.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.  PLoS Med. 2009;6(7):e1000100. doi:10.1371/journal.pmed.1000100. PubMedGoogle ScholarCrossref
19.
Hayden  JA, Côté  P, Bombardier  C.  Evaluation of the quality of prognosis studies in systematic reviews.  Ann Intern Med. 2006;144(6):427-437.PubMedGoogle ScholarCrossref
20.
OCEBM levels of evidence system. CEBM: Centre for Evidence-Based Medicine website. http://www.cebm.net/index.aspx?o=5653. Accessed October 1, 2012.
21.
DerSimonian  R, Laird  N.  Meta-analysis in clinical trials.  Control Clin Trials. 1986;7(3):177-188.PubMedGoogle ScholarCrossref
22.
Egger  M, Davey Smith  G, Schneider  M, Minder  C.  Bias in meta-analysis detected by a simple, graphical test.  BMJ. 1997;315(7109):629-634.PubMedGoogle ScholarCrossref
23.
Higgins  JP, Thompson  SG.  Quantifying heterogeneity in a meta-analysis.  Stat Med. 2002;21(11):1539-1558.PubMedGoogle ScholarCrossref
24.
Higgins  JP, Thompson  SG, Deeks  JJ, Altman  DG.  Measuring inconsistency in meta-analyses.  BMJ. 2003;327(7414):557-560.PubMedGoogle ScholarCrossref
25.
Asahina  A, Nakagawa  H, Etoh  T, Ohtsuki  M; Adalimumab M04-688 Study Group.  Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a phase II/III randomized controlled study.  J Dermatol. 2010;37(4):299-310.PubMedGoogle ScholarCrossref
26.
Braun  J, Deodhar  A, Dijkmans  B,  et al; Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group.  Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period.  Arthritis Rheum. 2008;59(9):1270-1278.PubMedGoogle ScholarCrossref
27.
Colombel  JF, Sandborn  WJ, Reinisch  W,  et al; SONIC Study Group.  Infliximab, azathioprine, or combination therapy for Crohn’s disease.  N Engl J Med. 2010;362(15):1383-1395.PubMedGoogle ScholarCrossref
28.
Emery  P, Fleischmann  R, Filipowicz-Sosnowska  A,  et al; DANCER Study Group.  The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.  Arthritis Rheum. 2006;54(5):1390-1400.PubMedGoogle ScholarCrossref
29.
Emery  P, Fleischmann  RM, Moreland  LW,  et al.  Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four–week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis.  Arthritis Rheum. 2009;60(8):2272-2283.PubMedGoogle ScholarCrossref
30.
Farrell  RJ, Alsahli  M, Jeen  YT, Falchuk  KR, Peppercorn  MA, Michetti  P.  Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trial.  Gastroenterology. 2003;124(4):917-924.PubMedGoogle ScholarCrossref
31.
Gottlieb  AB, Evans  R, Li  S,  et al.  Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial.  J Am Acad Dermatol. 2004;51(4):534-542.PubMedGoogle ScholarCrossref
32.
Hanauer  SB, Feagan  BG, Lichtenstein  GR,  et al; ACCENT I Study Group.  Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial.  Lancet. 2002;359(9317):1541-1549.PubMedGoogle ScholarCrossref
33.
Hyams  J, Crandall  W, Kugathasan  S,  et al; REACH Study Group.  Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children.  Gastroenterology. 2007;132(3):863-873, quiz 1165-1166.PubMedGoogle ScholarCrossref
34.
Inman  RD, Davis  JC  Jr, Heijde  Dv,  et al.  Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial.  Arthritis Rheum. 2008;58(11):3402-3412.PubMedGoogle ScholarCrossref
35.
Kavanaugh  A, Krueger  GG, Beutler  A,  et al; IMPACT 2 Study Group.  Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial.  Ann Rheum Dis. 2007;66(4):498-505.PubMedGoogle ScholarCrossref
36.
Kavanaugh  A, McInnes  I, Mease  P,  et al.  Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four–week efficacy and safety results of a randomized, placebo-controlled study.  Arthritis Rheum. 2009;60(4):976-986.PubMedGoogle ScholarCrossref
37.
Kay  J, Matteson  EL, Dasgupta  B,  et al.  Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study.  Arthritis Rheum. 2008;58(4):964-975.PubMedGoogle ScholarCrossref
38.
Keystone  EC, Genovese  MC, Klareskog  L,  et al; GO-FORWARD Study.  Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study.  Ann Rheum Dis. 2009;68(6):789-796.PubMedGoogle ScholarCrossref
39.
Kremer  J, Ritchlin  C, Mendelsohn  A,  et al.  Golimumab, a new human anti–tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: forty-eight–week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study.  Arthritis Rheum. 2010;62(4):917-928.PubMedGoogle ScholarCrossref
40.
Lichtenstein  GR, Diamond  RH, Wagner  CL,  et al.  Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials.  Aliment Pharmacol Ther. 2009;30(3):210-226.PubMedGoogle ScholarCrossref
41.
Lovell  DJ, Ruperto  N, Goodman  S,  et al; Pediatric Rheumatology Collaborative Study Group; Pediatric Rheumatology International Trials Organisation.  Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.  N Engl J Med. 2008;359(8):810-820.PubMedGoogle ScholarCrossref
42.
Maini  RN, Breedveld  FC, Kalden  JR,  et al; Anti–Tumor Necrosis Factor Trial in Rheumatoid Arthritis With Concomitant Therapy Study Group.  Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate.  Arthritis Rheum. 2004;50(4):1051-1065.PubMedGoogle ScholarCrossref
43.
Mease  PJ, Cohen  S, Gaylis  NB,  et al.  Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial.  J Rheumatol. 2010;37(5):917-927.PubMedGoogle ScholarCrossref
44.
Menter  A, Tyring  SK, Gordon  K,  et al.  Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial.  J Am Acad Dermatol. 2008;58(1):106-115.PubMedGoogle ScholarCrossref
45.
Miyasaka  N; CHANGE Study Investigators.  Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study.  Mod Rheumatol. 2008;18(3):252-262.PubMedGoogle ScholarCrossref
46.
Papp  K, Crowley  J, Ortonne  JP,  et al.  Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy.  Br J Dermatol. 2011;164(2):434-441.PubMedGoogle ScholarCrossref
47.
Ruperto  N, Lovell  DJ, Cuttica  R,  et al; Paediatric Rheumatology International Trials Organisation; Pediatric Rheumatology Collaborative Study Group.  A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis.  Arthritis Rheum. 2007;56(9):3096-3106.PubMedGoogle ScholarCrossref
48.
Ruperto  N, Lovell  DJ, Cuttica  R,  et al; Paediatric Rheumatology International Trials Organization (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG).  Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension.  Ann Rheum Dis. 2010;69(4):718-722.PubMedGoogle ScholarCrossref
49.
Rutgeerts  P, Sandborn  WJ, Feagan  BG,  et al.  Infliximab for induction and maintenance therapy for ulcerative colitis.  N Engl J Med. 2005;353(23):2462-2476.PubMedGoogle ScholarCrossref
50.
Sandborn  WJ, Feagan  BG, Stoinov  S,  et al; PRECISE 1 Study Investigators.  Certolizumab pegol for the treatment of Crohn’s disease.  N Engl J Med. 2007;357(3):228-238.PubMedGoogle ScholarCrossref
51.
Sandborn  WJ, Hanauer  SB, Rutgeerts  P,  et al.  Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial.  Gut. 2007;56(9):1232-1239.PubMedGoogle ScholarCrossref
52.
Sandborn  WJ, Schreiber  S, Feagan  BG,  et al.  Certolizumab pegol for active Crohn’s disease: a placebo-controlled, randomized trial.  Clin Gastroenterol Hepatol.2011;9(8):670-678.e3. doi:10.1016/j.cgh.2011.04.031.PubMedGoogle ScholarCrossref
53.
Sands  BE, Anderson  FH, Bernstein  CN,  et al.  Infliximab maintenance therapy for fistulizing Crohn’s disease.  N Engl J Med. 2004;350(9):876-885.PubMedGoogle ScholarCrossref
54.
Schreiber  S, Khaliq-Kareemi  M, Lawrance  IC,  et al; PRECISE 2 Study Investigators.  Maintenance therapy with certolizumab pegol for Crohn’s disease.  N Engl J Med. 2007;357(3):239-250.PubMedGoogle ScholarCrossref
55.
van den Bemt  BJ, den Broeder  AA, Wolbink  GJ,  et al.  Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusion cycle: an open-label pharmacokinetic cohort study.  BMC Musculoskelet Disord. 2011;12:12.PubMedGoogle ScholarCrossref
56.
Abe  T, Takeuchi  T, Miyasaka  N,  et al.  A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis.  J Rheumatol. 2006;33(1):37-44.PubMedGoogle Scholar
57.
Bender  NK, Heilig  CE, Dröll  B, Wohlgemuth  J, Armbruster  F-P, Heilig  B.  Immunogenicity, efficacy and adverse events of adalimumab in RA patients.  Rheumatol Int. 2007;27(3):269-274.PubMedGoogle ScholarCrossref
58.
Ducourau  E, Mulleman  D, Paintaud  G,  et al.  Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases.  Arthritis Res Ther. 2011;13(3):R105. doi:10.1186/ar3386. PubMedGoogle ScholarCrossref
59.
Finckh  A, Dudler  J, Wermelinger  F,  et al; Physicians of SCQM.  Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients.  Joint Bone Spine. 2010;77(4):313-318.PubMedGoogle ScholarCrossref
60.
Geborek  P, Saxne  T, Kapetanovic  MC, Larsson  L, Svensen  M, Bendtzen  K.  Serum TNF-binding capacity and drug antibody development are useful for monitoring rheumatoid arthritis patients treated with infliximab in clinical practice [abstract].  Ann Rheum Dis. 2005;64(suppl III):414.Google Scholar
61.
Klareskog  L, Wajdula  J, Baker  P, Fatenejad  S.  Low and transient auto- and anti-etanercept antibody formation has no measurable impact on clinical outcomes during 5 years of etanercept (Enbrel) treatment in patients with rheumatoid arthritis [abstract].  Ann Rheum Dis.2006;65(suppl I):325.Google ScholarCrossref
62.
Pascual-Salcedo  D, Plasencia  C, Ramiro  S,  et al.  Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis.  Rheumatology (Oxford). 2011;50(8):1445-1452.PubMedGoogle ScholarCrossref
63.
Radstake  TR, Svenson  M, Eijsbouts  AM,  et al.  Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis.  Ann Rheum Dis. 2009;68(11):1739-1745.PubMedGoogle ScholarCrossref
64.
Arends  S, Lebbink  HR, Spoorenberg  A,  et al.  The formation of autoantibodies and antibodies to TNF-α blocking agents in relation to clinical response in patients with ankylosing spondylitis.  Clin Exp Rheumatol. 2010;28(5):661-668.PubMedGoogle Scholar
65.
Davis  J, Peng  JZ, Noertersheuser  PA, Paulson  S, Van der Heijde  D, Schiff  D.  Pharmacokinetics of adalimumab in patients with active ankylosing spondylitis (AS)—the Atlas trial [abstract].  Ann Rheum Dis. 2006;65(suppl II):537.Google ScholarCrossref
66.
de Vries  MK, Wolbink  GJ, Stapel  SO,  et al.  Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation.  Ann Rheum Dis. 2007;66(9):1252-1254.PubMedGoogle ScholarCrossref
67.
de Vries  MK, Brouwer  E, van der Horst-Bruinsma  IE,  et al.  Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation.  Ann Rheum Dis. 2009;68(11):1787-1788.PubMedGoogle ScholarCrossref
68.
Plasencia  C, Pascual-Salcedo  D, Bonilla  MG,  et al.  Influence of immunogenicity on the efficacy of long-term treatment with infliximab in spondyloarthritis [abstract].  Arthritis Rheum. 2011;63(suppl 10):2636.Google Scholar
69.
Adişen  E, Aral  A, Aybay  C, Gürer  MA.  Anti-infliximab antibody status and its relation to clinical response in psoriatic patients: a pilot study.  J Dermatol. 2010;37(8):708-713.PubMedGoogle ScholarCrossref
70.
Lecluse  LLA, Driessen  RJB, Spuls  PI,  et al.  Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis.  Arch Dermatol. 2010;146(2):127-132.PubMedGoogle ScholarCrossref
71.
Hoffmann  JH, Hartmann  M, Enk  AH, Hadaschik  EN.  Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction.  Br J Dermatol. 2011;165(6):1355-1358.PubMedGoogle ScholarCrossref
72.
van Kuijk  AW, de Groot  M, Stapel  SO, Dijkmans  BA, Wolbink  GJ, Tak  PP.  Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis.  Ann Rheum Dis. 2010;69(3):624-625.PubMedGoogle ScholarCrossref
73.
Afif  W, Loftus  EV  Jr, Faubion  WA,  et al.  Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease.  Am J Gastroenterol. 2010;105(5):1133-1139.PubMedGoogle ScholarCrossref
74.
Ainsworth  MA, Bendtzen  K, Brynskov  J.  Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn’s disease.  Am J Gastroenterol. 2008;103(4):944-948.PubMedGoogle ScholarCrossref
75.
Ben-Horin  S, Yavzori  M, Katz  L,  et al.  The immunogenic part of infliximab is the F(ab’)2, but measuring antibodies to the intact infliximab molecule is more clinically useful.  Gut. 2011;60(1):41-48.PubMedGoogle ScholarCrossref
76.
Karmiris  K, Paintaud  G, Noman  M,  et al.  Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s disease.  Gastroenterology. 2009;137(5):1628-1640.PubMedGoogle ScholarCrossref
77.
Steenholdt  C, Bendtzen  K, Brynskov  J, Thomsen  OO, Ainsworth  MA.  Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn’s disease.  Scand J Gastroenterol. 2011;46(3):310-318.PubMedGoogle ScholarCrossref
78.
West  RL, Zelinkova  Z, Wolbink  GJ, Kuipers  EJ, Stokkers  PCF, van der Woude  CJ.  Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease.  Aliment Pharmacol Ther. 2008;28(9):1122-1126.PubMedGoogle ScholarCrossref
79.
Felson  DT, Anderson  JJ, Boers  M,  et al;  American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis.  Arthritis Rheum. 1995;38(6):727-735.PubMedGoogle ScholarCrossref
80.
Fransen  J, van Riel  PL.  The Disease Activity Score and the EULAR response criteria.  Clin Exp Rheumatol. 2005;23(5)(suppl 39):S93-S99.PubMedGoogle Scholar
81.
Anderson  JJ, Baron  G, van der Heijde  D, Felson  DT, Dougados  M.  Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis.  Arthritis Rheum. 2001;44(8):1876-1886.PubMedGoogle ScholarCrossref
82.
Stroup  DF, Berlin  JA, Morton  SC,  et al; Meta-analysis of Observational Studies in Epidemiology (MOOSE) group.  Meta-analysis of observational studies in epidemiology: a proposal for reporting.  JAMA. 2000;283(15):2008-2012.PubMedGoogle ScholarCrossref
83.
Dickersin  K, Min  YI, Meinert  CL.  Factors influencing publication of research results: follow-up of applications submitted to two institutional review boards.  JAMA. 1992;267(3):374-378.PubMedGoogle ScholarCrossref
84.
Biggerstaff  BJ, Tweedie  RL.  Incorporating variability in estimates of heterogeneity in the random effects model in meta-analysis.  Stat Med. 1997;16(7):753-768.PubMedGoogle ScholarCrossref
85.
Hwang  WY, Foote  J.  Immunogenicity of engineered antibodies.  Methods. 2005;36(1):3-10.PubMedGoogle ScholarCrossref
86.
Emi Aikawa  N, de Carvalho  JF, Artur Almeida Silva  C, Bonfá  E.  Immunogenicity of anti–TNF-α agents in autoimmune diseases.  Clin Rev Allergy Immunol. 2010;38(2-3):82-89.PubMedGoogle ScholarCrossref
87.
Fransen  J, Stucki  G, van Riel  P.  The merits of monitoring: should we follow all our rheumatoid arthritis patients in daily practice?  Rheumatology (Oxford). 2002;41(6):601-604.PubMedGoogle ScholarCrossref
88.
Wolfe  F, Cush  JJ, O’Dell  JR,  et al.  Consensus recommendations for the assessment and treatment of rheumatoid arthritis.  J Rheumatol. 2001;28(6):1423-1430.PubMedGoogle Scholar
89.
Vander Cruyssen  B, Van Looy  S, Wyns  B,  et al.  DAS28 best reflects the physician’s clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment.  Arthritis Res Ther. 2005;7(5):R1063-R1071.PubMedGoogle ScholarCrossref
90.
van der Bijl  AE, Breedveld  FC, Antoni  CE,  et al.  An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status.  Clin Rheumatol. 2008;27(8):1021-1028.PubMedGoogle ScholarCrossref
91.
Yazici  Y, Shi  N, John  A.  Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy.  Bull NYU Hosp Jt Dis. 2008;66(2):77-85.PubMedGoogle Scholar
92.
Gómez-Reino  J.  Biologic monotherapy as initial treatment in patients with early rheumatoid arthritis.  Rheumatology (Oxford). 2012;51(suppl 5):v31-v37.PubMedGoogle ScholarCrossref
Original Investigation
August 12/26, 2013

Immunogenicity of Monoclonal Antibodies Against Tumor Necrosis Factor Used in Chronic Immune-Mediated Inflammatory Conditions: Systematic Review and Meta-analysis

Author Affiliations
  • 1Rheumatology Unit, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago, Spain
  • 2Department of Medicine, Medical School, Universidad de Santiago, Santiago, Spain
JAMA Intern Med. 2013;173(15):1416-1428. doi:10.1001/jamainternmed.2013.7430
Abstract

Importance  Knowledge of the immunogenicity of biologic agents may be helpful for the development of strategies for treatment of chronic immune-mediated inflammatory diseases.

Objective  To summarize the influence of antibodies against biologic agents (AABs [seropositivity]) on efficacy and safety in immune-mediated inflammatory diseases.

Data Sources  MEDLINE, EMBASE, Cochrane Library, and the Web of Knowledge were searched for articles published in English, Spanish, French, Italian, or Portuguese between 2000 and March 2012. The search strategy focused on synonyms of diseases, immunogenicity, and biologic agents. Abstracts from 2001 to 2011 of the European League Against Rheumatism and American College of Rheumatology congresses were also included.

Study Selection  The selection criteria were (1) observational or interventional studies in rheumatoid arthritis, juvenile idiopathic arthritis, inflammatory bowel disease, spondyloarthritis, and psoriasis; (2) studies including patients who received biologic agents; and (3) studies collecting data on AABs.

Data Extraction and Synthesis  Data collected included publication details, study design, characteristics of patients and treatments, presence of antibodies, and definition of response.

Main Outcomes and Measures  The primary end point was the association of AABs with response to treatment. Secondary end points were the association of AABs with safety, the association of AABs with concentration of the drug, and the influence of use of concomitant immunosuppressive therapy in the formation of AABs.

Results  The search captured 10 728 articles and abstracts. By hand and reverse search, 31 articles were additionally included. After evaluation of the full reports, 60 references were selected. They included 59 studies of anti–tumor necrosis factor monoclonal antibodies: 1 with etanercept, 2 with rituximab, and 2 with abatacept. In rheumatoid arthritis but not in inflammatory bowel disease or spondyloarthritis, seropositive patients presented worse clinical response at 6 months or less (odds ratio [OR], 0.03; 95% CI, 0.01-0.21), and at 6 months or more (0.03; 0.00-0.30) by meta-analysis. In rheumatoid arthritis, discontinuation of the biologic agent for all reasons was more common in seropositive patients (OR, 3.53; 95% CI, 1.60-7.82). In all conditions, seropositive patients had a higher risk of hypersensitivity reactions (OR, 3.97; 95% CI, 2.36-6.67). Overall, concomitant treatment with disease-modifying antirheumatic drugs, including azathioprine, decreased the risk of seropositivity (OR, 0.32; 95% CI, 0.25-0.42).

Conclusions and Relevance  Presence of antibodies against anti–tumor necrosis factor monoclonal antibodies confers a risk of discontinuation of treatment in rheumatoid arthritis and a risk of development of hypersensitivity reactions in all immune-mediated inflammatory diseases. The combined use of anti–tumor necrosis factor monoclonal antibodies and disease-modifying antirheumatic drugs reduces the development of antibodies and subsequent risks. Information on other biologic agents is fragmentary.

×